MDGL
USDMadrigal Pharmaceuticals Inc. Common Stock
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$488.030
Kõrge
$494.550
Madal
$477.000
Maht
0.76M
Ettevõtte fundamentaalnäitajad
Turukapitalisatsioon
11.1B
Tööstusharu
Biotehnoloogia
Riik
United States
Kauplemisstatistika
Keskmine maht
0.37M
Börs
NMS
Valuuta
USD
52 nädala vahemik
Seotud uudised
B of A Securities Upgrades Madrigal Pharmaceuticals to Neutral, Raises Price Target to $445
B of A Securities analyst Alexandria Hammond upgrades Madrigal Pharmaceuticals from Underperform to Neutral and raises the price target from $266 to $445.
Madrigal to Present New Data from the Company's MASH Program at AASLD's The Liver Meeting 2025
Two oral presentations to highlight biomarker, imaging and quality-of-life data from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial of RezdiffraPoster of distinction examines the
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
CONSHOHOCKEN, Pa., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated
Truist Securities Initiates Coverage On Madrigal Pharmaceuticals with Buy Rating, Announces Price Target of $580
Truist Securities analyst Srikripa Devarakonda initiates coverage on Madrigal Pharmaceuticals with a Buy rating and announces Price Target of $580.
Seotud aktsiad
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.